Page 146 - Haematologica March 2020

J. Woo et al.
17. Itzykson R, Kosmider O, Renneville A, et al.
Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013;31(19):2428-2436.
18. Wattel E, Guerci A, Hecquet B, et al. A ran- domized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group. Blood. 1996;88(7): 2480-2487.
19. Solary E, Itzykson R. How I treat chronic myelomonocytic leukemia. Blood. 2017;130 (2):126-136.
20. Zandberg DP, Huang TY, Ke X, et al. Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults. Haematologica. 2013;98(4):584-590.
21. Eissa H, Gooley TA, Sorror ML, et al. Allogeneic hematopoietic cell transplanta- tion for chronic myelomonocytic leukemia: relapse-free survival is determined by kary- otype and comorbidities. Biol Blood Marrow Transplant. 2011;17(6):908-915.
22. Elliott MA, Tefferi A, Hogan WJ, et al. Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. Bone Marrow Transplant. 2006;37(11):1003-1008.
23. Itonaga H, Aoki K, Aoki J, et al. Prognostic impact of donor source on allogeneic hematopoietic stem cell transplantation out- comes in adults with chronic myelomono- cytic leukemia: a nationwide retrospective analysis in Japan. Biol Blood Marrow Transplant. 2018;24(4):840-848.
24. Kerbauy DM, Chyou F, Gooley T, et al. Allogeneic hematopoietic cell transplanta- tion for chronic myelomonocytic leukemia. Biol Blood Marrow Transplant. 2005;11(9): 713-720.
25. Liu HD, Ahn KW, Hu ZH, et al. Allogeneic hematopoietic cell transplantation for adult chronic myelomonocytic leukemia. Biol Blood Marrow Transplant. 2017;23(5): 767- 775.
26. Motohashi K, Fujisawa S, Doki N, et al. Cytogenetic risk stratification may predict
allogeneic hematopoietic stem cell trans- plantation outcomes for chronic myelomonocytic leukemia. Leuk Lymphoma. 2018;59(6):1332-1337.
27. Symeonidis A, van Biezen A, de Wreede L, et al. Achievement of complete remission predicts outcome of allogeneic haematopoi- etic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. Br J Haematol. 2015;171(2):239-246.
28. Such E, Cervera J, Costa D, et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica. 2011;96(3):375-383.
29. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring sys- tem for myelodysplastic syndromes. Blood. 2012;120(12):2454-2465.
30. Sorror ML. How I assess comorbidities before hematopoietic cell transplantation. Blood. 2013;121(15):2854-2863.
31. Martin P, Nash R, Sanders J, et al. Reproducibility in retrospective grading of acute graft-versus-host disease after allo- geneic marrow transplantation. Bone Marrow Transplant. 1998;21(3):273-279.
dations from an international expert panel.
Blood. 2017;129(13):1753-1762.
36. Zang DY, Deeg HJ, Gooley T, et al.
Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplan- tation. Br J Haematol. 2000;110(1):217-222.
37. Barba P, Ratan R, Cho C, et al. Hematopoietic cell transplantation comor- bidity index predicts outcomes in patients with acute myeloid leukemia and myelodysplastic syndromes receiving CD34(+) selected grafts for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2017;23(1):67-74.
38. Makishima H, Yoshizato T, Yoshida K, et al. Dynamics of clonal evolution in myelodys- plastic syndromes. Nat Genet. 2017;49(2): 204-212.
39. Lindsley RC, Saber W, Mar BG, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017;376(6):536-547.
40. Deeg HJ, Scott BL, Fang M, et al. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoiet- ic cell transplantation for MDS or acute leukemia evolving from MDS. Blood. 2012;120(7):1398-1408.
41. Shi J, Wang E, Milazzo JP, Wang Z, Kinney JB, Vakoc CR. Discovery of cancer drug tar- gets by CRISPR-Cas9 screening of protein domains. Nat Biotechnol. 2015;33(6):661-
32. Przepiorka D, Weisdorf D, Martin P, et al.
1994 Consensus Conference on acute
GVHD grading. Bone Marrow Transplant. 1995;15(6):825-828. 667.
33. Peng Q, Vijaya Satya R, Lewis M, Randad P, Wang Y. Reducing amplification artifacts in high multiplex amplicon sequencing by using molecular barcodes. BMC Genomics. 2015;16:589.
34. Woo J, Howard NP, Storer BE, et al. Mutational analysis in serial marrow sam- ples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syn- dromes. Haematologica. 2017;102(6):e216- e218.
35. de Witte T, Bowen D, Robin M, et al. Allogeneic hematopoietic stem cell trans- plantation for MDS and CMML: recommen-
42. Herbaux C, Duployez N, Badens C, et al. Incidence of ATRX mutations in myelodys- plastic syndromes, the value of microcyto- sis. Am J Hematol. 2015;90(8):737-738.
43. Steensma DP, Higgs DR, Fisher CA, Gibbons RJ. Acquired somatic ATRX mutations in myelodysplastic syndrome associated with alpha thalassemia (ATMDS) convey a more severe hematologic phenotype than germline ATRX mutations. Blood. 2004;103(6):2019-2026.
44. Rampal R, Figueroa ME. Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemia. Haematologica. 2016;101(6):672-679.
660
haematologica | 2020; 105(3)